Impact of a modified peritoneal cancer index using FDG-PET/CT (PET-PCI) in predicting tumor grade and progression-free survival in patients with pseudomyxoma peritonei.


Journal

European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 06 12 2018
accepted: 11 02 2019
revised: 17 01 2019
pubmed: 16 3 2019
medline: 18 12 2019
entrez: 16 3 2019
Statut: ppublish

Résumé

The peritoneal cancer index (PCI) is widely used for assessing pseudomyxoma peritonei (PMP) in surgery. The aim of this study was to evaluate the utility of a modified PCI using 18F-fluorodeoxyglucose (18F-FDG)-PET/CT (PET-PCI) for predicting pathologic grade and progression-free survival (PFS) in patients with PMP. Thirty-five patients who underwent 18F-FDG-PET/CT before cytoreductive surgery and/or hyperthermic intraperitoneal chemotherapy were enrolled. PET-PCI was determined by summing up the visually scored 18F-FDG uptake of PMP lesions in 13 specific abdominal-pelvic regions. Uptake score was defined as 0, no lesion or lesion without uptake; 1, slight uptake less than or equivalent to mediastinal blood pool; 2, moderate uptake above mediastinal but below or equal to liver; and 3, intense uptake moderately to markedly higher than liver. SUVmax of the lesion was also evaluated. Pathologic diagnosis revealed 19 patients with low-grade PMP and 16 patients with high-grade PMP. Patients with high-grade PMP showed significantly higher PET-PCI and SUVmax than patients with low-grade PMP (PET-PCI 14.8 vs. 8.7, p = 0.007; SUVmax 3.6 vs. 2.6, p = 0.013). Using a cutoff PET-PCI of 12, Kaplan-Meier analyses showed a significant difference in PFS between patients with high and low PET-PCI (p < 0.001; hazard ratio (HR), 12.4). For SUVmax, the optimal cutoff was 2.7 and the correlation with PFS was also significant (p = 0.008; HR, 4.7). In multivariate Cox proportional-hazards regression, PET-PCI was independently and significantly correlated with PFS. PET-PCI can reflect histopathologic features and appears useful for predicting recurrence in patients with PMP. • Peritoneal cancer index using 18F-FDG-PET/CT (PET-PCI) has great potential for predicting progression-free survival in patients with pseudomyxoma peritonei. • PET-PCI provides higher prognostic performance than maximum standardized uptake value (SUVmax). • PET-PCI shows high correlation with histopathologic grade of pseudomyxoma peritonei.

Identifiants

pubmed: 30874878
doi: 10.1007/s00330-019-06102-1
pii: 10.1007/s00330-019-06102-1
doi:

Substances chimiques

Radiopharmaceuticals 0
Fluorodeoxyglucose F18 0Z5B2CJX4D

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5709-5716

Références

J Am Coll Surg. 2006 Dec;203(6):878-86
pubmed: 17116556
J Am Coll Surg. 1995 Dec;181(6):530-8
pubmed: 7582228
Eur J Cancer. 2001 May;37(8):979-84
pubmed: 11334722
Eur J Surg Oncol. 2006 Aug;32(6):597-601
pubmed: 16617003
Ann Surg Oncol. 1999 Dec;6(8):727-31
pubmed: 10622499
Int J Gynecol Pathol. 2014 Jan;33(1):1-10
pubmed: 24300528
J Clin Oncol. 2009 Dec 20;27(36):6237-42
pubmed: 19917862
J Clin Pathol. 2012 Oct;65(10):919-23
pubmed: 22718846
Oncotarget. 2017 Apr 27;8(33):55657-55683
pubmed: 28903452
Am J Surg Pathol. 2016 Jan;40(1):14-26
pubmed: 26492181
Ann Surg. 2011 Aug;254(2):294-301
pubmed: 21772129
J Surg Oncol. 2004 May 1;86(2):64-73
pubmed: 15112247
Mod Pathol. 2015 Jan;28 Suppl 1:S67-79
pubmed: 25560600
Oncotarget. 2017 May 16;8(20):33884-33896
pubmed: 27980228
Ann Surg Oncol. 2011 Jun;18(6):1582-9
pubmed: 21207170
J Gastrointest Surg. 2012 Apr;16(4):762-70
pubmed: 22258877
Eur J Gynaecol Oncol. 2004;25(4):411-4
pubmed: 15285293
Surg Oncol Clin N Am. 2012 Oct;21(4):611-23
pubmed: 23021719
Ann Surg Oncol. 2010 Sep;17(9):2330-40
pubmed: 20232161
Oncotarget. 2016 Dec 13;7(50):83544-83553
pubmed: 27835875
Eur J Surg Oncol. 2008 Feb;34(2):196-201
pubmed: 17524597
Arch Pathol Lab Med. 2011 Oct;135(10):1261-8
pubmed: 21970481
J Gastrointest Surg. 2016 Feb;20(2):307-12
pubmed: 26162922
J Clin Oncol. 2012 Jul 10;30(20):2449-56
pubmed: 22614976
Medicine (Baltimore). 2017 Aug;96(33):e7813
pubmed: 28816978
Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1630-7
pubmed: 26907364
Eur J Surg Oncol. 2009 Oct;35(10):1078-84
pubmed: 19285828
Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):27-38
pubmed: 21946983
Am J Surg Pathol. 1995 Dec;19(12):1390-408
pubmed: 7503361
J Surg Oncol. 2008 Sep 15;98(4):277-82
pubmed: 18726894

Auteurs

Masatoshi Hotta (M)

Department of Radiology, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan. masatoshihotta@yahoo.co.jp.

Ryogo Minamimoto (R)

Department of Radiology, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan.

Yoshimasa Gohda (Y)

Department of Surgery, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan.

Toru Igari (T)

Department of Pathology, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan.

Hideaki Yano (H)

Department of Surgery, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH